Clever Leaves Exports Its First Commercial Shipment of THC Flower to the United States to Biopharmaceutical Research Company
06 Oktober 2021 - 2:30PM
Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW)
(“Clever Leaves” or the “Company”), a leading multinational
operator and licensed producer of pharmaceutical-grade
cannabinoids, announced today the exportation of 30 kg of high-THC
cannabis flower from its Portugal facility to Biopharmaceutical
Research Company (“BRC”), a DEA-licensed pharmaceutical company
that develops federally compliant active pharmaceutical ingredients
(API) for plant-based therapeutics in the United States. Not only
does this fortify Clever Leaves’ entrance into the U.S. and
solidify BRC’s ability to transact internationally, but it
positions the two organizations as some of the first companies ever
to commercially ship dried cannabis flower from Portugal to the
U.S.
Under the agreement, Clever Leaves’ product,
which meets strict pharmaceutical standards, will be used for BRC’s
pharmaceutical development projects. In addition to this shipment
of dried cannabis flower, BRC and Clever Leaves have built a strong
partnership over the past year through their collaboration in
Project Change Lives, an initiative announced earlier this year to
contribute up to USD$25M in medical cannabis products to help
advance scientific research in the U.S.
“Exporting THC flower to BRC, a DEA-licensed
company located in the U.S., not only represents an important
commercial milestone for Clever Leaves, but it demonstrates our
capabilities to determine and execute upon a viable regulatory
pathway to enter the U.S., the largest cannabis market in the
world,” said Kyle Detwiler, CEO of Clever Leaves. “By becoming one
of the first companies to commercially export THC flower to the
U.S., we are paving Clever Leaves’ path into the U.S. medical
cannabis industry through a partner such as BRC. We are honored to
provide BRC the high-quality product they need to advance in their
research, development, and production.”
“Our partnership with Clever Leaves continues to
yield exciting research opportunities that will one day make a
difference in the lives of patients,” said George Hodgin, CEO of
Biopharmaceutical Research Company. “Both companies share the same
values when it comes to DEA compliance—we take it seriously—which
is why we believe this partnership is only getting started. We are
thrilled to partner with Clever Leaves once again and are eager to
begin working with this premium quality product.”
Clever Leaves’ Portuguese cultivation facility
is located on approximately 9 million square feet of land and
consists of approximately 110,000 square feet of high technology
greenhouse facilities with expansion to approximately 270,000
square feet nearly complete. The facility was granted a license
from INFARMED I.P., the Portuguese regulatory authority with
oversight over the pharmaceutical industry in Portugal, for
importing, exporting, and cultivating cannabis. Our
state-of-the-art sophisticated facilities in Portugal, which are
Good Agricultural and Collecting Practice (GACP) certified, are
currently operational and commercially active, with successful
exports to various countries, including Australia.
About Clever Leaves Holdings
Inc.Clever Leaves is a multinational cannabis company with
an emphasis on ecologically sustainable, large-scale cultivation
and pharmaceutical-grade cannabinoid processing as the cornerstones
of its global cannabis business. With operations and investments in
the United States, Canada, Colombia, Germany and Portugal, Clever
Leaves has created an effective distribution network and global
footprint, with a foundation built upon capital efficiency and
rapid growth. Clever Leaves aims to be one of the industry’s
leading global cannabis companies recognized for its principles,
people, and performance while fostering a healthier global
community. Clever Leaves has received multiple international
certifications that have enabled it to increase its export and
sales capacity from its Colombian operations, including European
Union Good Manufacturing Practices (EU GMP) Certification, a Good
Manufacturing Practices (GMP) Certification by Colombia National
Food and Drug Surveillance Institute - Invima, and Good
Agricultural and Collecting Practices (GACP) Certification. Clever
Leaves was granted a license in Portugal from Infarmed – the
Portuguese health authority – which allows Clever Leaves to
cultivate, import and export dry flower for medicinal and research
purposes. In addition, the Portuguese operation was also granted
certification of compliance with GACP and IMC-GAP.
About Biopharmaceutical Research
CompanyBiopharmaceutical Research Company (“BRC”), a
DEA-licensed pharmaceutical company that develops federally
compliant active pharmaceutical ingredients (API) for plant-based
therapeutics in the United States. BRC is pioneering the federally
legal cannabis space in the U.S.
Clever Leaves Press
contacts:McKenna Miller KCSA Strategic Communications
+1-347-487-6197cleverleaves@kcsa.com
Diana SigüenzaStrategic
Communications
Director+57-310-236-8830Diana.siguenza@cleverleaves.com
Clever Leaves Investor
Inquiries:Cody Slach and Jackie KeshnerGateway Investor
Relations+1-949-574-3860CLVR@gatewayir.com
Clever Leaves Commercial
Inquiries:Andrew MillerVice President Sales - EMEA, North
America, and
Asia-Pacific+1-416-817-1336andrew.miller@cleverleaves.com
BRC Press contact:Charlie
PattersonSquared Communications(202)
680-8132charlie@sqcomms.com
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
Von Jul 2023 bis Jul 2024